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Tapentadol is a novel centrally acting drug that combines mu-opioid receptor (MOR) agonism and
noradrenaline reuptake inhibition (NRI), producing analgesic effects in various painful conditions. We
investigated the acute effects of tapentadol in the locus coeruleus (LC), a central nucleus regulated by the
noradrenergic and opioid systems that is critical in pain modulation. In single-unit extracellular re-
cordings of LC neurons from anaesthetized male SpragueeDawley rats, tapentadol clearly inhibited the
spontaneous electrophysiological activity of LC neurons in a dose-dependent manner (ED50 ¼ 0.8 mg/kg).
This inhibitory effect was reversed by RX821002 (an alpha2-adrenoceptor antagonist) and naloxone (a
mu-opioid receptor antagonist) by 96.7% and 28.2%, respectively. Pretreatment with RX821002, N-
ethoxycarbonyl-2-ethoxy-1-2-dihydroquinoline (EEDQ, an irreversible alpha2-adrenoceptor antagonist)
or naloxone shifted the tapentadol doseeeffect curve to the right (ED50 ¼ 2.2 mg/kg, 2.0 mg/kg and
2.1 mg/kg, respectively). Furthermore, tapentadol inhibited the LC response to mechanical stimulation of
the hindpaw in a dose-dependent manner. In summary, we demonstrate that acute administration of
tapentadol inhibits LC neurons in vivo, mainly due to the activation of alpha2-adrenoceptors. These data
suggest that both the noradrenergic and opioid systems participate in the inhibitory effect of tapentadol
on LC neurons, albeit to different extents, which may account for its potent analgesic effect and mild
opioidergic side-effects.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Tapentadol, a new drug for pain treatment, was developed
based on the known synergistic interaction between opioid and
noradrenergic mechanisms at the spinal and supraspinal levels
(Jordan et al., 2003; Ossipov et al., 1997, 1990). Tapentadol
HCl, ()-(1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-
phenol hydrochloride, is an analgesic that acts centrally and that
combines two mechanisms of action in a single non-racemic
molecule: that of a mu-opioid receptors (MOR) agonist and as a
noradrenaline reuptake inhibitor (NRI). Tapentadol is currently
prescribed as an alternative to classic opioids for the treatment of
moderate to severe acute and chronic pain (Daniels et al., 2009;
Kavanagh et al., 2012; Xu et al., 2012). Indeed, despite its 50-fold
lower affinity for MOR, tapentadol is only 2- to 3-fold less potent, University of Cadiz, Campus
al, Cadiz, Spain. Tel.: þ34
coso).
All rights reserved.than morphine in inducing analgesia in preclinical models of pain,
yet with a better tolerance and physical dependence profile
(Tzschentke et al., 2006, 2007).
While several recent studies have investigated the mechanism
of action of tapentadol at the behavioural and spinal level, it re-
mains to be determined how tapentadol modulates the descending
noradrenergic pathway. The locus coeruleus (LC) is the main site of
noradrenergic cell bodies in the brain and an essential modulator of
pain and opiate action. Noradrenaline is an important endogenous
analgesic in the spinal cord and it is released by bulbospinal
noradrenergic axons that project from LC neurons (see review in:
Pertovaara, 2006). LC activity is tonically regulated by somato-
dendritic and terminal alpha2-adrenoceptors (alpha2-AR), which
inhibit noradrenaline release (Mateo and Meana, 1999; Starke,
2001). Activation of these Gi-protein-coupled receptors leads to a
progressive increase in potassium conductance and cell hyperpo-
larization (Aghajanian and Wang, 1986). Accordingly, their direct
activation with agonists or indirect activation with NRI (e.g., anti-
depressants such as desipramine and venlafaxine) dampens the
electrical activity of these neurons in a dose-dependent manner
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2001; Valentino et al., 1990). The LC also contains a high density
of MOR that act as heteroreceptors to inhibit LC electrical activity,
as well as modulating opiate tolerance and dependence (review in:
Nestler et al., 1999).
The aim of the present study was to characterize the effects of
systemic tapentadol administration on the electrical activity of LC
neurons, and to determine the relative contributions of the
noradrenergic and opioid systems to this effect. In addition, we
compared the effects of tapentadol on LC neurons with those of the
NRI desipramine and of the MOR agonist morphine. Finally, we
studied the effect of tapentadol on the LC response to the me-
chanical stimulation of the hindpaw (sensory-evoked LC activity).
2. Materials and methods
2.1. Animals
Experiments were performed on adult male SpragueeDawley rats (bodyweight,
200e300 g), which were housed in polycarbonate cages in groups of four under
standard laboratory conditions (22 C, 12 h light/dark cycle, lights on at 08:00 AM,
food and water ad libitum). The animals were acclimatised for at least 7 days prior to
the initiation of the study, and every effort was made to minimize animal suffering
and to use the smallest possible number of animals. All procedures and animal
handling were carried out in accordance with the European Commission’s directive
2010/63/EU and Spanish Law (RD 1201/2005) regulating animal research.
2.2. Drugs
All drug solutions were prepared immediately before each trial and all the drugs
were dissolved in physiological saline (0.9% NaCl), with the exception of EEDQ (N-
ethoxycarbonyl-2-ethoxy-1-2-dihydroquinoline) which was dissolved in ethanol
and then diluted sequentially in propylene glycol and water (0.25:0.25:0.50, v/v/v).
All the drugs were administered intravenously (i.v.), except for EEDQ which was
injected intraperitoneally (i.p.). The following drugs were used: tapentadol HCl
(Grünenthal GmbH, Germany), idazoxan (IDX), naloxone hydrochloride (NLX),
EEDQ, desipramine hydrochloride (Sigma Chemicals, USA), morphine (Spanish
Ministry of Health, Spain) and RX821002 hydrochloride (Tocris Bioscience, UK). The
doses usedwere selected on the basis of previous successful experiments carried out
in our laboratory and data available in the literature. Naloxone was injected intra-
venously at 5 mg/kg, a dose that blocks the effect of opioid compounds on LC
neurons (Ruiz-Durantez et al., 2003). Idazoxan and RX821002 were injected at
100 mg/kg i.v., a dose previously shown to reverse the inhibitory effects of alpha2-AR
agonists on LC neurons (Alba-Delgado et al., 2012a; Biyah and Advenier, 1995). EEDQ
(6 mg/kg, i.p.) was administered 6 h before commencing electrophysiological re-
cordings, as this duration is required to achieve complete blockade of alpha2-AR
(Pineda et al., 1997).
2.3. Electrophysiological recordings in anesthetized rats
Single-unit extracellular recordings of LC neurons were performed as described
previously (Berrocoso et al., 2006). Rats were first anesthetized with an i.p. injection
of chloral hydrate (400 mg/kg) and subsequently, anaesthesia was maintained using
a perfusion pump (60e70mg/kg/h). The animal’s body temperaturewasmaintained
at 37 C with a heated pad. Next, the rat was placed in a stereotaxic frame (DavidFig. 1. Effect of tapentadol on the spontaneous firing activity of locus coeruleus (LC) neuro
showing the recording site in the LC (black arrow: 4V, 4th ventricle). (BeC) Representative h
inhibitory effect of tapentadol. This effect was reversed by subsequent intravenous admin
bar ¼ 1 min). (D) Doseeresponse curve showing the inhibitory effect of tapentadol (n ¼
(mean  SEM). The horizontal axis represents the logarithm of cumulative tapentadol doseKopf Instrument, USA) with its head at an angle of 15 to the horizontal plane (nose
down) and the recording electrode was lowered into the LC (3.7 mm caudal to
lambda, e 1.1 mm lateral to the midline suture and 5.0e6.0 mm ventral to the dural
surface; Paxinos and Watson, 2009). The recording electrode was a single-barrel
pulled glass micropipette filled with a 2% solution of Pontamine Sky Blue in 0.5%
sodium acetate. The extracellular signals from the electrode were amplified with a
high-input impedance amplifier and monitored. Discriminated spikes were fed into
a PC and processed using CED Micro1401 and Spike2 computer software (UK). LC
neurons were identified based on the following well-established criteria: long
duration action potential (>2 ms), spontaneous firing at a regular rhythm, a slow
firing rate between 0.5 and 5 Hz and characteristic spikes with a long-lasting pos-
itive-negative waveform. At the end of the experiments, the recording site was
marked by passing a 5 mA cathodic current through the electrode to leave a blue spot.
In this way brain sections could ultimately be stainedwith neutral red and examined
microscopically (Fig.1A). Onlymeasurements from cells within the LCwere included
in the analysis.
2.4. Experimental design
2.4.1. Spontaneous firing activity
When a single LC unit was isolated, the spontaneous basal discharge was
recorded at least 2 min prior to drug administration and it was assessed in terms of:
(i) firing rate (Hz); (ii) coefficient of variation (expressed as the percentage ratio of
the standard deviation to the mean interval value of an interspike time-interval
histogram); and (iii) burst firing rate (burst/s). A LC cell was considered to exhibit
burst firing when it displayed at least two spikes with an initial interspike interval
<80ms andwith subsequent interspike intervals160ms (Grace and Bunney,1984:
see Table 1). Doseeresponse curves were then generated for tapentadol by injecting
the drug at 2 min intervals, in doubling doses, until all spontaneous activity ceased
(maximal effect). Subsequent injections of NLX (MOR antagonist, 5 mg/kg), IDX
(alpha2-AR antagonist, 100 mg/kg) or RX821002 (selective alpha2-AR antagonist,
100 mg/kg) were administered to determine if they reversed the inhibitory effect of
tapentadol. To characterize the relative noradrenergic and opioid components of
tapentadol-mediated inhibition of spontaneous LC neuronal activity, RX821002
(100 mg/kg) or NLX (5 mg/kg) were administered 2 min before performing tapen-
tadol doseeresponse experiments. In both assays, the inhibitory effect of tapentadol
was reversed by i.v. administration of NLX (5 mg/kg) or RX821002 (100 mg/kg). In
addition, the irreversible alpha2-AR antagonist EEDQ (6 mg/kg) was administered
6 h before performing tapentadol doseeresponse experiments. The complete inhi-
bition of spontaneous activity induced by tapentadol was reversed by NLX admin-
istration (5 mg/kg). Finally, to compare the effect of tapentadol on LC neurons with
that of desipramine andmorphine, doseeresponse experiments were performed for
both drugs. Desipramine or morphine was administered in increasing doubling
doses at 3 and 2 min intervals, respectively, until electrical activity ceased. The ca-
pacity of IDX (100 mg/kg) or NLX (1 mg/kg) to reverse this inhibitory effect was then
quantified.
Changes in firing rate were expressed as a percentage of the basal firing rate and
in reversion studies, they were expressed as the percentage recovery with respect to
the basal firing rate. Doseeresponse curves were analysed for the best non-linear fit
to the following logistic three-parameter equation (Parker and Waud, 1971):
E¼ Emax [C]n/(ED50n þ [C]n), where [C] is the i.v. dose of drug; E is the effect of the drug
on the firing rate; Emax is the maximal percentage change at “infinite” dose (100%);
ED50 is the effective dose that elicits 50% of Emax, and n is the slope factor of the
function. Only one doseeresponse curve was obtained per rat.
2.4.2. Sensory-evoked firing activity
The LC evoked response was recorded in another set of animals. Accordingly,
three consecutive mechanical compressions of the hindpaw were applied beforens. (A) Photomicrograph of a coronal section (Neutral Red stain) of the rat brainstem
istogram from firing rate recordings of LC neurons demonstrating the dose-dependent
istration of (B) naloxone (NLX) and idazoxan (IDX), or (C) RX821002 and NLX (scale
8). Symbols represent the percentage reduction with respect to the basal firing rate
s.
Table 2
Summary of the ED50 and the reversal of tapentadol-induced inhibition.
Group ED50 (mg/kg) Reversion studies (%)
Tapentadol 0.8  0.1 (8) NLX IDX#
28.2  0.9 26.4  7.3
RX821002 NLX#
96.7  4.6 18.9  0.8
RX821002 þ Tapentadol 2.2  0.4* (7) NLX
59.5  10.2
EEDQ þ Tapentadol 2.0  0.4* (6) NLX
75.7  7.6
NLX þ Tapentadol 2.1  0.2* (6) RX821002
79.8  2.8
Desipramine 0.2  0.1$$ (5) IDX
29.8  7.3
Morphine 1.0  0.2 (5) NLX&
94.3  6.6
Data are expressed as the mean  S.E.M. The effective dose 50 (ED50) was estimated
from the doseeresponse curves for tapentadol, desipramine or morphine. The
values within parentheses represent the number of pharmacologically tested neu-
rons. The reversal of tapentadol-induced inhibition is expressed as the percentage of
recovery of the firing rate by a single i.v. dose of naloxone (NLX, 5 mg/kg or 1 mg/
kg&), idazoxan (IDX, 100 mg/kg) or RX821002 (100 mg/kg). #The effect of the second
drug (IDX or NLX) administered in the reversion studies is expressed as the per-
centage of recovery of the residual activity. *p < 0.05 vs tapentadol group (one-way
analysis of variance test followed by Tukey’s multiple comparison test), $$p< 0.01 vs
tapentadol group (Student’s t-test).
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(0.3e2.4 mg/kg). Each paw compression lasted for 1.0 s, delivered at 2.0 s intervals
using a pair of 15.0 cm surgical forceps (Ref. 501742-G, World Precision Instruments,
UK) and applying pressuremidway along the forceps such that the opposite leaves of
the forceps came into contact. Such stimuli evoked a burst discharge followed by
post-activation inhibition or suppression (Fig. 4A: Grant and Weiss, 2001). A LC
neuron was considered to exhibit a sensory-evoked response when it displayed at
least two spikes, with an interspike interval <160 ms (defined as a burst event). This
response was assessed in terms of: (i) incidence, i.e., the proportion of cells exhib-
iting an evoked response; (ii) latency (ms), the time to the onset of the response to
the stimulus; (iii) number of sensory-evoked responses per train; (iv) number of
spikes per train; and (v) period of suppression (s), i.e., the time after each evoked
response in which there was no neuronal activity.
2.5. Data analysis
All the data are presented as the mean  S.E.M. and they were analysed with
Prism 5.0 GraphPad (GraphPad, USA). As no differences were found between the
spontaneous electrical parameters of LC neurons before pharmacological treatment,
these data were pooled for analysis (“baseline”, Table 1). Student’s t-test was used to
compare values between two groups. Comparisons of more than two groups were
performed with a one-way analysis of variance (ANOVA) followed by the Tukey’s
multiple comparison test (Table S1). The Fisher’s exact test was used to analyse two
categorical variables. A p < 0.05 was considered as significant.
3. Results
3.1. Acute effect of tapentadol on the electrical activity of LC
neurons
Tapentadol administration (0.3e4.8 mg/kg) inhibited sponta-
neous activity in the LC in a dose-dependent manner. Complete
inhibition was achieved in all cells tested and the mean ED50 value
estimated from doseeresponse curves was 0.8  0.1 mg/kg
(Fig. 1D). This complete inhibition of firing activity was reversed
(28.2  0.9%) by NLX (5 mg/kg) administration, while subsequent
IDX (100 mg/kg) administration produced a further reversal of the
residual activity of 26.4  7.3% (total reversion of 54.5  6.7%
respect to basal activity: Fig. 1B and Table 2). As IDX also displays
significant affinity for other receptors expressed in the LC (Hoyer,
1988; Miralles et al., 1993; Newman-Tancredi et al., 1998), addi-
tional studies were performed using this selective alpha2-AR
antagonist, RX821002. Accordingly, the inhibitory effect of tapen-
tadol was reversed by RX821002 (96.7  4.6%), while subsequent
NLX administration resulted in a further reversal of 18.9  0.8% of
the residual activity (total reversion of 115.5  3.9% respect to basal
activity: Fig. 1C and Table 2).
3.2. Effect of alpha2-AR blockade on the tapentadol-induced
inhibition of LC activity
The contribution of alpha2-AR to the inhibitory effect of
tapentadol in LC neurons was studied using two approaches. Firstly,Table 1








Baseline 1.5  0.1 36.3  2.5 0.010  0.004 29
RX821002 (100 mg/kg) 2.0  0.3 47.4  5.9 0.017  0.007 7
EEDQ (6 mg/kg) 3.5  0.2*** 59.4  2.3*** 0.169  0.050*** 17
Naloxone (5 mg/kg) 1.4  0.2 34.1  5.7 0.002  0.002 6
Data are expressed as the mean S.E.M of n cells per group. The distinct parameters
were obtained from the locus coeruleus neurons in basal conditions (before any
pharmacological treatment), and after a single i.v. dose of RX821002 (selective
alpha2-adrenoceptor antagonist) or naloxone (opioid receptor antagonist), and after
i.p. pretreatment with N-ethoxycarbonyl-2-ethoxy-1-2-dihydroquinoline (EEDQ,
irreversible alpha2-adrenoceptor antagonist) administered 6 h before recording:
***p < 0.001 vs baseline (one-way analysis of variance test followed by Tukey’s
multiple comparison test).rats were pretreated with RX821002 (100 mg/kg) 2 min before
tapentadol administration, this exposure to RX821002 producing
no effect on the basal firing properties of LC neurons (p > 0.05;
Fig. 2A, Table 1). However, the doseeresponse curve of tapentadol
was shifted to the right when administered after RX821002, and
the ED50 increased by 175.0% (ED50 tapentadol 0.8  0.1 mg/kg;
ED50 RX821002 þ tapentadol 2.2  0.4 mg/kg: p < 0.05; Fig. 2B,
Tables 2 and S1). The complete inhibition of LC neurons following
RX821002 þ tapentadol administration was reversed by
59.5  10.2% following the subsequent administration of NLX
(5 mg/kg; Fig. 2A and Table 2).
Pretreatment with the irreversible alpha2-AR antagonist, EEDQ
(6 mg/kg), 6 h before tapentadol administration significantly
increased spontaneous firing: the mean basal firing rate (p < 0.001,
Table S1), the regular firing pattern (variation coefficient; p< 0.001,
Table S1) and the burst firing (p < 0.001, Table S1) of LC neurons
compared to the basal parameters (Table 1: Pineda et al., 1997). In
these conditions, the doseeresponse curve of tapentadol shifted to
the right and the ED50 increased by 150% (ED50 tapentadol
0.8 0.1mg/kg; ED50 EEDQþ tapentadol 2.0 0.4mg/kg: p< 0.05;
Fig. 2D, Tables 2 and S1). Total inhibition was observed in all neu-
rons tested, an effect that was rapidly reversed by subsequent
administration of NLX (5 mg/kg, 75.7  7.6%; Fig. 2C and Table 2).3.3. Effect of opioid receptor blockade on tapentadol-induced
inhibition of LC activity
NLX administration had no effect on the basal firing properties
of LC neurons (p > 0.05; Fig. 2E, Tables 1 and S1: Berrocoso and
Mico, 2007; Berrocoso et al., 2006; Illes and Norenberg, 1990) and
thus, we also examined the effects of administering NLX (5 mg/kg)
2 min before generating tapentadol doseeresponse curves. This
opioid receptor blockade shifted the tapentadol doseeresponse
curve to the right and increased the ED50 by 162.5%when compared
with the control group (ED50 tapentadol 0.8  0.1 mg/kg; ED50
NLX þ tapentadol 2.1  0.2 mg/kg: p < 0.05; Fig. 2F, Tables 2 and
S1). This shift was similar to that induced by pretreatment with
RX821002 and EEDQ (p > 0.05; NLX vs RX821002; NLX vs EEDQ;
Table S1). Complete inhibition of firing was observed in all neurons
Fig. 2. Inhibitory effect of RX821002, EEDQ or naloxone (NLX) on the spontaneous firing activity of locus coeruleus (LC) neurons induced by tapentadol. (A, C, E) Representative
histograms of the firing rate recordings to show the effect of tapentadol after pretreatment with RX821002, EEDQ (6 h prior) and NLX, respectively. The inhibitory effect of
tapentadol was reversed by subsequent administration of (A, C) NLX or (E) RX821002 (scale bar ¼ 1 min). (B, D, F) Doseeresponse curves showing the inhibitory effect of tapentadol
in the control group (Tap, n ¼ 8) and after pretreatment with (B) RX821002 (RX821002 þ Tap, n ¼ 7), (D) EEDQ (EEDQ þ Tap, n ¼ 6) or (F) NLX (NLX þ Tap, n ¼ 6). Symbols represent
the percentage reduction with respect to the basal firing rate (mean  SEM). The horizontal axis represents the logarithm of the cumulative tapentadol doses.
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79.8  2.8% by subsequent RX821002 (100 mg/kg) administration
(Fig. 2E and Table 2).3.4. Comparison of the effects of tapentadol with those of
desipramine and morphine
The administration of desipramine (0.05e1.60 mg/kg) or
morphine (0.15e4.80 mg/kg) inhibited spontaneous LC activity in a
dose-dependent manner (Fig. 3A and C) and complete inhibition
was observed in all the cells tested. The mean ED50 value estimated
from the doseeresponse curve for desipraminewas 0.2 0.0mg/kg
(Fig. 3B). Subsequent IDX administration (100 mg/kg) reversed the
total inhibition of spontaneous LC activity by desipramine by29.8  7.3% with respect to basal activity (Fig. 3A and Table 2), an
effect similar to that observed in the tapentadol doseeresponse
experiments (Fig. 1B and Table 2). The mean ED50 value for
morphine estimated from the doseeresponse curves was
1.0  0.2 mg/kg (Fig. 3D) and subsequent NLX administration
(1 mg/kg) reversed the total inhibition of spontaneous LC activity
induced by morphine by 94.3  6.6% (Fig. 3C and Table 2).3.5. Acute effect of tapentadol on the sensory-evoked activity of LC
neurons
Mechanical hindpaw stimulation evoked the well-documented
response of LC neurons in all the cells tested, characterized by a
marked increase in the spikes after paw compression followed by a
Fig. 3. Effects of desipramine and morphine on the spontaneous firing activity of locus coeruleus (LC) neurons. (A, C) Representative histograms of firing rate recordings from LC
neurons showing the dose-dependent inhibition by desipramine and morphine. These effects were reversed by subsequent administration of (A) idazoxan (IDX) or (C) naloxone
(NLX: scale bar ¼ 1 min). The doseeresponse curves demonstrate the inhibitory effect of (B) desipramine and (D) morphine (both n ¼ 5), and the symbols represent the percentage
reduction with respect to the basal firing rate (mean  SEM). The logarithm of the cumulative drug doses is reflected in the horizontal axis. (E) Estimated 50% effective dose (ED50)
taken from the doseeresponse curves for desipramine (n ¼ 5), tapentadol (n ¼ 8) and morphine (n ¼ 5). The affinity constants (Ki) for the mu-opioid receptors (MOR) and
noradrenaline transporter (NAT) reflect the ligand concentrations (mM) determined in MOR-binding and synaptosomal monoamine reuptake assays in the rat brain (Sanchez and
Hyttel, 1999; Tzschentke et al., 2007): **p < 0.01 vs desipramine (Student’s t-test).
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2001). After tapentadol administration, the number of cells that
responded to the mechanical stimulus was reduced to 33% and 0%
at doses of 1.2 and 2.4 mg/kg, respectively. Accordingly, this drug
reduced both the number of responses, as well as the number of
spikes in each response, in dose-dependent manner (Fig. 4C and D,
Tables 3 and S1).
4. Discussion
The present study demonstrates that systemic tapentadol
administration inhibits the spontaneous and mechanically-evoked
firing of LC neurons in vivo in a dose-dependent manner. The effecton spontaneous activity is associated with the activation of both
alpha2-AR and MOR. These results confirm the dual mechanism of
action of acute tapentadol administration at the level of the LC, in
agreement with previous behavioural findings in models of acute
and chronic pain, and electrophysiological data from spinal neu-
rons (Bee et al., 2011; Christoph et al., 2010; Kogel et al., 2011;
Tzschentke et al., 2007).
The inhibitory effect of tapentadol on LC neurons appears to be
mediated by both the noradrenergic and opioid systems, albeit to
different extents. This effect was almost entirely reversed by
RX821002, but only partially by NLX treatment, suggesting that
alpha2-AR primarily mediate the acute inhibitory effect of tapen-
tadol on LC neurons. The activation of alpha2-AR in the LC
Fig. 4. Effect of tapentadol (Tap) on the sensory-evoked firing activity of locus coeruleus (LC) neurons. (A) Schematic representation of a typical LC neuron response to mechanical
stimulation (black triangle). (BeD) Representative oscillography traces illustrating the sensory-evoked response of LC neurons to a train of mechanical stimuli. The notches in upper
traces of each panel represent the burst events at the (B) baseline (before tapentadol), and after administration of (C) 0.3 mg/kg and (D) 1.2 mg/kg tapentadol. Note the progressive
inhibition of LC response produced by tapentadol.
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firing rate via a negative feedback loop (Svensson et al., 1975);
whereas the blockade of alpha2-AR enhances the LC firing rate, as
evident following exposure to the irreversible antagonist EEDQ.
Administration of an NRI (e.g., desipramine) produces an increase in
the availability of noradrenaline in the synaptic cleft at the LC and
terminal level. This results in alpha2-AR activation in the LC and
ultimately, inhibition of the neuronal firing that in part counteracts
the effects of desipramine on the terminal (Mateo et al., 1998).
Accordingly, the inhibition of spontaneous LC firing by NRI provides
a measure of alpha2-AR agonist activity in the LC, reflecting the
increase in noradrenaline bioavailability in terminal areas. Micro-
dialysis studies have demonstrated that tapentadol produces a
dose-dependent increase in extracellular levels of noradrenaline in
LC projection areas, such as the spinal cord and hippocampus
(Tzschentke et al., 2007, 2012). Thus, like NRI, tapentadol is likely to
produce a similar increase in extracellular noradrenaline at the LC
level, which would activate inhibitory alpha2-AR, inhibiting LC
activity and partially counteracting the net amount of noradrena-
line released at both the LC and terminal levels (spinal cord and
hippocampus). In agreement with this rationale, it was previously
shown that local microinjection of alpha2-AR antagonists into the
LC produces analgesia that is reduced by intrathecal alpha2-AR
antagonists (Wei and Pertovaara, 2006), suggesting that spinal
and LC alpha2-AR have opposite effects on pain-related behaviour.
However, it is important to note that tapentadol does not bind to
any adrenergic receptors (neither alpha2-AR nor other subtypes).
Since tapentadol blocks noradrenaline reuptake, it will (indirectly)
activate all types of adrenergic receptors that are present in the
system. Until now the analgesic effect of tapentadol was blocked by
the systemic administration of alpha2-AR antagonists (Schroder
et al., 2010), presumably acting on primary afferent neuronsTable 3
Sensory-evoked firing activity of locus coeruleus neurons.
Incidence (%) Latency (ms) Number
Baseline 100.0 (6/6) 113.3  43.3 2.3  0.3
Tapentadol doses
0.3 mg/kg 75.0 (3/4) 103.3  58.1 1.0  0.4
0.6 mg/kg 100.0 (4/4) 27.5  18.9 1.3  0.3
1.2 mg/kg 33.3 (1/3) w 0.3  0.3
2.4 mg/kg 0.0 (0/2)$ w 0.0  0.0
Data represent the mean  S.E.M. LC activity evoked by a train of mechanical stimuli. The
The values in parentheses represent the LC neurons ratio exhibiting evoked response. Th
variance test followed by Tukey’s multiple comparison test). The incidence was analysed
was not observed.(Fig. 5) given that tapentadol’s inhibitory effects on evoked re-
sponses of spinal dorsal horn neurons were reversed by the spinal
blockade of alpha2-AR in anaesthetized animals (Bee et al., 2011).
We now show that this effect might be partially counteracted in
anaesthetized animals by alpha2-AR activity in the LC. These data
suggest that the spinal activation of alpha2-AR predominates over
that of the LC in the global analgesic effect of tapentadol.
Conversely, NLX reversed the inhibitory effect of tapentadol,
although less so than RX821002. The role of opioid signalling in LC
activity is of particular interest, as MOR in the LC play a key role in
mediating opiate dependence and withdrawal. Acute morphine
administration acts on MOR to enhance the opening of inwardly-
rectifying potassium channels, resulting in hyperpolarization.
However, chronic morphine treatment impairs the ability of MOR
to open potassium channels, leading to the development of toler-
ance and dependence (Aghajanian, 1978; Rasmussen et al., 1990).
The mild activation of MOR by tapentadol may explain the milder
physical dependence associated with this compound than with
traditional opioids (Tzschentke et al., 2006). Overall the decrease of
LC activity through a predominant alpha2-AR dependent mecha-
nism rather than MOR activation would contribute to a mild
opioidergic side effect. Thus, further behavioural studies using local
tapentadol administration into LC would be necessary to elucidate
this issue.
To determine the relative contribution of alpha2-AR to the ef-
fects of tapentadol observed, we administered the selective alpha2-
AR antagonist RX821002 prior tapentadol. This antagonist pro-
voked a shift of the tapentadol doseeresponse curve to the right,
increasing the ED50, as also occurred after pretreatment with the
irreversible alpha2-AR antagonist EEDQ, indicating that alpha2-AR
antagonism attenuated the inhibitory effect of tapentadol. Subse-
quent administration of NLX reversed the inhibitory effect ofof responses Spikes per response Suppression period (s)
6.5  0.6 2.0  0.2
6.3  0.7 1.6  0.1
4.8  0.9 1.1  0.3*
* w w
* w w
pattern of the response was measured before (baseline) and after tapentadol doses.
e factor significance was represented as *p < 0.05 vs baseline (one-way analysis of
by Fisher’s exact test: $p < 0.05 vs baseline. w, not listed as sensory-evoked activity
Fig. 5. Scheme representing the hypothetical effect of tapentadol on pain circuits in basal conditions and following mechanical stimulation. (A) In basal conditions (untreated), locus
coeruleus (LC) neurons fire tonically and release noradrenaline (basal NA) at the level of the soma (1) and terminals (spinal cord, 2), under the negative control of presynaptic
alpha2-AR and neurotransmitter reuptake. The influence of the ascending nociceptive pathway, transmitted to the LC by the paragigantocellularis nucleus (PGi: basal glutamate,
Glu), is very weak. (B) Inhibition of noxious information at the level of the spinal cord is triggered by nociceptive inputs to the LC. When a mechanical stimulation (untreated) is
elicited, nociceptive inputs enter the spinal cord through primary afferents (3), which strongly activate the fibres of the spinoreticular tract (4). The input along the ascending
pathway rises to the PGi (5), which in turn sends an excitatory amino acid input to the LC (evoked Glu). Excitatory inputs produce a sensory-evoked response of LC neurons,
resulting in an increase of firing activity and NA release (evoked NA) at the LC (6) and in the spinal cord (7). This effect is partially counteracted by the activation of alpha2-AR in the
LC. (C) Acute tapentadol administration produces the blockade of noradrenaline transporters (NAT) at the LC and spinal level, as well as activation of the MOR. The increase of NA
availability will mainly inhibit LC activity through the activation of LC alpha2-AR. (D) In conditions of mechanical stimulation, the ascending noxious inputs to the LC are reduced as
tapentadol augments the spinal NA and opioidergic activity (mu-opioid receptor, MOR), resulting in a weaker sensory-evoked response at the LC level.
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the opioid-mediated inhibition in the LC, as indicated previously
(Illes and Norenberg, 1990; Schoffelmeer et al., 1986). This suggests
that the concomitant activation of alpha2-AR andMOR produced by
tapentadol decreases the global opioid effects at LC level. This
reduced activation of MOR in LC neurons may explain the mild
opioidergic side effects of tapentadol. Administration of NLX prior to
tapentadol treatment increased the ED50 of tapentadol and inter-
estingly, similar ED50 values were obtained by inhibiting alpha2-AR
or opioid receptors. Moreover, subsequent RX821002 administra-
tion reversed the effect of tapentadol to levels comparable to those
of untreated animals (79.8% vs 96.7%). Taken together, these findings
confirm that the inhibitory effects of tapentadol are mediated by the
activation of both alpha2-AR and MOR.
The potency of tapentadol was higher than that expected based
on its Ki values for noradrenaline transporter (NAT) and MOR
(Fig. 3E). Indeed, the inhibitory effect of tapentadol was comparable
to that induced by morphine in the same neurons, even though the
affinity of tapentadol for MOR was 50-fold lower than that of
morphine (Ki ¼ 0.096 and 0.002 mM, respectively: Tzschentke et al.,
2007). The potent effects of tapentadol appear to be mainly due to
its inhibition of noradrenaline reuptake, although the NRI activity
of tapentadol was more moderate than that of desipramine
(Ki ¼ 0.48 and 0.0008 mM, respectively: Sanchez and Hyttel, 1999).
These observations suggest that an interaction between both re-
ceptor systems underlies the overall effect of tapentadol. A number
of behavioural studies have demonstrated that signalling via both
neurotransmitter systems is required for the potent analgesic ef-
fects of tapentadol, both in preclinical models of pain (Tzschentke
et al., 2006) and in isobolographic studies (Schroder et al., 2011).
This may be because alpha2-AR and MOR activate the same intra-
cellular signalling pathways to promote potassium channel open-
ing, thereby dampening neuronal excitability. However, although
MOR and alpha2-AR are concomitantly involved in the inhibitory
effect of tapentadol on LC activity, the contribution of latter appears
to be stronger than that of the former.
In addition to inhibiting the spontaneous firing rate of LC neu-
rons, tapentadol also inhibits the acute noxious-evoked response in
a dose-dependent manner. It has been shown that the inhibition of
nociceptive information at the spinal cord level by the LC is trig-
gered by nociceptive inputs to the LC, forming a feedback loop
(Fig. 5). Indeed, noxious hindpaw stimulation will activate the
ascending pain pathway, such as the glutamatergic nucleus para-
gigantocellularis (PGi: Chiang and Aston-Jones, 1993; Ennis and
Aston-Jones, 1988), which will in turn activate LC neurons,
thereby increasing the noradrenaline release at the spinal cord
level. Thus, the ascending noxious information will allow LC neu-
rons to engage descending feedback systems that regulate the
output from the spinal cord (Fig. 5A and B). Administration of
tapentadol enhances the availability of noradrenaline and MOR
activation in the spinal cord, which will reduce LC sensory-evoked
activity when the hindpaw is stimulated, given that the dampening
of the transmission of the acute noxious information from the
spinal cord (Fig. 5C and D). This is consistent with the noradren-
ergic impact of tapentadol in acute models of pain (Kogel et al.,
2011; Schroder et al., 2010). However, additional studies in
models of neuropathic pain will be necessary to confirm this hy-
pothesis given that predominant noradrenergicmediation has been
demonstrated in pathological pain states (Schroder et al., 2010;
Tzschentke et al., 2007). In this sense, we recently demonstrated
that alpha2-AR and NAT function are initially preserved when an-
imals are subjected to chronic constriction injury (Alba-Delgado
et al., 2012a), indicating that tapentadol probably exerts similar
effects at the LC level to those described here in conditions of
neuropathic pain. However, increased LC alpha2-AR and NATfunction have been described after long term neuropathic pain
(Alba-Delgado et al., 2013), and it remains unknown whether MOR
expression and/or activity is altered in this condition. In addition, it
will be important to determine if chronic tapentadol treatment
desensitizes alpha2-AR and/or NAT at the LC level, as happens with
other NRI (Alba-Delgado et al., 2012b), or if they sensitize MOR as
occurs with morphine (Dang and Williams, 2004).
5. Conclusions
In conclusion, tapentadol induces a dose-dependent inhibition of
the electrical activity of LC neurons by activating both alpha2-AR and
MOR, both of which are required to achieve a maximal effect.
Moreover, our data demonstrate the predominant role of alpha2-AR,
which probably accounts for the milder tolerance and dependence
associated with tapentadol than with other opioidergic analgesics.
Further electrophysiological studies in pathological pain conditions
(e.g., neuropathies) will be required to define the mechanism of
action of tapentadol and related compounds more precisely.
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